Euvolemic Hyponatremia
0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
OtsukaJapan - Tokushima
1 programHyponatremia Registry for Patients With Euvolemic and Hypervolemic HyponatremiaN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
BiogenLixivaptan
OtsukaHyponatremia Registry for Patients With Euvolemic and Hypervolemic Hyponatremia
Clinical Trials (2)
Total enrollment: 5,234 patients across 2 trials
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Oral Lixivaptan Capsules in Subjects With Euvolemic Hyponatremia
Start: Jun 2009206 patients
Phase 3Completed
Hyponatremia Registry for Patients With Euvolemic and Hypervolemic Hyponatremia
Start: Sep 2010Est. completion: Aug 20135,028 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.